ADMP - アダミス・ファ―マス―ティカルズ (Adamis Pharmaceuticals Corporation) アダミス・ファ―マス―ティカルズ



symbol ADMP
会社名 Adamis Pharmaceuticals Corp. (アダミス・ファ―マス―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company''s product portfolio includes specialty pharmaceutical products such as Epinephrine pre-filled syringe (PFS) APC-5000 dry powder inhaler (DPI) APC-1000 and APC-2000 and biotechnology products such as TeloB-VAX (vaccine) APC-100 APC-200 and APC-300. The Company''s lead product candidate the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe or the Epinephrine PFS is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.   アダミス・ファ―マス―ティカルズは米国の医薬品会社。アナフィラキシ―(急性の全身過敏症)、喘息、慢性閉塞性肺疾患、アレルギ―性鼻炎治療のネピネフリン自己注射剤、ドライパウダ―吸入器、吸入ステロイド薬の治験を行う。また、前立腺がんのテロメラ―ゼ阻害剤を治験中。本社はカリフォルニア州サンディエゴ。   Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company that develops & commercializes products in the therapeutic areas of respiratory disease & allergy. Its products include Epinephrine Injection PFS syringe, APC-1000, APC-2000, & APC-5000.
本社所在地 11682 El Camino Real Suite 300 San Diego CA 92130 USA
代表者氏名 Richard C. Williams リチャード・C・ウィリアムズ
代表者役職名 Independent Chairman of the Board
電話番号 +1 858-997-2400
設立年月日 32660
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 126人
EBITDA EBITDA(百万ドル) -28.29893
終値(lastsale) 3.09
時価総額(marketcap) 146130296.22
時価総額 時価総額(百万ドル) 144.23860
売上高 売上高(百万ドル) 13.32986
企業価値(EV) 企業価値(EV)(百万ドル) 145.65953
当期純利益 当期純利益(百万ドル) -22.70772
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Adamis Pharmaceuticals Corp revenues increased 4% to $7.1M. Net loss increased 61% to $17.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase from $2.7M to $7.1M (expense) Selling general_administrative expense increase of 14% to $12.8M (expense).



   Adamis Pharmaceuticals' (ADMP) CEO Dennis Carlo on Q1 2019 Results - Earnings Call Transcript  2019-05-10
Adamis Pharmaceuticals Corporation (ADMP) Q1 2019 Results Earnings Conference Call May 9, 2019 5:00 PM ET Company Participants Dennis Carlo President and Chief Executive Officer Rob Hopkins Chief Financial Officer Ronald Moss Chief Medical Officer Dav…
   Adamis Pharmaceuticals Is Poised For A Sharp Rebound  2019-04-25
Source: BigCharts Long-suffering shareholders have seemingly thrown in the towel on Adamis ( ADMP ) - again! When will they ever learn? Just over the past year, ADMP has fallen and rebounded many times (see my earlier article) . Interestingly, the stock penetrated a lower technical suppor…
   Adamis Pharmaceuticals: Refused, Accepted, Missed, And Predictable  2019-03-21
Adamis Pharmaceuticals ( ADMP ) has reverted to its old ways of a mixed bag of information compiled over multiple press releases with little clarification from the CEO Dr. Dennis J. Carlo. The company finished 2018 with filing two NDAs and started 2019 with the launch of their flagship pro…

 関連キーワード  (医薬品 米国株 アダミス・ファ―マス―ティカルズ ADMP Adamis Pharmaceuticals Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)